Clinical trials
Small Cell Lung Carcinoma clinical trials
Below are recruiting small cell lung carcinoma clinical trials, each written for real people, not researchers. We’re tracking 748 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06125041RecruitingPhase 2
Adebelizumab with chemo and radiation for advanced lung cancer
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
Jinan, ShandongAges 18–75 - NCT07167459Enrolling by invitationPhase 2
Personalized radiation for early stage lung cancer
This trial tests a personalized radiation treatment called SBRT for early-stage non-small cell lung cancer that is located in the outer part of the lung and cannot be removed with surgery. The goal is to see if this approach works well for people who cannot have surgery or choose not to.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05382728RecruitingPhase 3
Test drug for EGFR-mutant lung cancer without prior treatment
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Changsha, HunanAges 18–80 - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT07089199RecruitingPhase 2
Drug combo before surgery for stage III lung cancer
This trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery for stage III lung cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
Jinan, ShandongAges 18–75 - NCT06911606RecruitingPhase 2
Serplulimab with chemotherapy before surgery for limited-stage small cell lung cancer
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
Guangzhou, GuangdongAges 18–75 - NCT06739928RecruitingPhase 2
Irinotecan liposome with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
Guangzhou, GuangzhouAges 18–70 - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75 - NCT06738160RecruitingPhase 2
Combination therapy for bone metastases from advanced lung cancer
This trial tests adding a new drug (narlumosbart) and targeted radiation to standard chemotherapy and immunotherapy for people with advanced non-small cell lung cancer that has spread to the bones. The goal is to see if this combination works better than standard treatment alone.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07087223RecruitingPhase 1/Phase 2
Study of vebreltinib plus furmonertinib for NSCLC with c-Met amplification
This trial tests a combination of two targeted therapies (vebreltinib and furmonertinib) for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a change called c-Met amplification and has stopped responding to earlier EGFR-targeted treatment. It aims to see if adding vebreltinib can help control the cancer.
Neimeng, NeimengAges 18 years+ - NCT06853678Recruiting
Immunotherapy after first treatment for extensive stage small cell lung cancer
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT07322783RecruitingPhase 2
Osimertinib plus savolitinib for resistant lung cancer
This trial tests a combination of two targeted drugs (osimertinib and savolitinib) for people with a specific type of advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help patients whose cancer has a low number of MET gene copies.
QingdaoAges 18–80 - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+ - NCT05745350RecruitingPhase 2
First treatment for extensive-stage small cell lung cancer
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06668103RecruitingPhase 2
Study of ABSK043 and Firmonertinib for EGFR-mutant lung cancer
This study tests a new combination of two targeted therapies (ABSK043 and firmonertinib) for people with a specific type of advanced lung cancer. It is for patients whose tumors have an EGFR mutation and are PD-L1 positive.
Hefei, AnhuiAges 18 years+ - NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06517953RecruitingPhase 2
Testing two targeted pills for rare EGFR lung cancer
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Guangzhou, GuangdongAges 18 years+ - NCT04270591RecruitingPhase 1/Phase 2
Glumetinib for lung cancer with MET changes
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Louisville, KentuckyAges 18–80 - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT05798845RecruitingPhase 2
Toripalimab plus radiation before surgery for stage II–IIIA lung cancer
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07082179RecruitingPhase 2
Immunotherapy plus chemotherapy for stage III lung cancer
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
NanjingAges 18–75 - NCT05815173RecruitingPhase 1
Ladarixin plus sotorasib for KRAS-mutated lung cancer
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
Garden City, New YorkAges 18–100
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell lung carcinoma?
- Yes. Clin2 currently lists 748 recruiting small cell lung carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell lung carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.